Approved Study Database

Ref. No. Scientific Title Principal investigator
2013.047 An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A Dr. LI Chi Kong
2011.607 An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B Dr. Li Chi Kong
2011.606 An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A Dr. Li Chi Kong
2017.178 A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia Prof. LI Chi Kong
李志光教授
2016.643 Genotyping variants determining mercaptopurine tolerance in Chinese children with Acute Lymphoblastic Leukaemia Prof. LI Chi Kong
李志光
2016.406 Genomic study on inherited bone marrow failure syndromes in Hong Kong by next generation sequencing Prof. LI Chi Kong
李志光
2017.012 Asian-wide, multicenter open-label, phase II non-randomised study involving children with Down syndrome under 21 year-old with newly diagnosed, treatment naïve acute lymphoblastic leukemia Prof. LI Chi Kong
李志光
2017.355 miRNA as diagnostic biomarkers for early detection of brain damage in acute leukaemia Prof. LI Chi Kong
李志光
2015.023 Acute Lymphoblastic Leukaemia, Chinese Children Cancer Leukaemia Group 2015 Study Dr. LI Chi Kong
2017.610 To study the effect of Syk inhibition or deletion on terminal erythropoiesis of human thalassemic hematopoietic and stem progenitors Prof. LI Chi Kong
李志光教授
2017.607 Chinese Children Cancer Group Relapsed ALL 2017 Study Prof. LI Chi Kong
李志光
2017.625 International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones: EsPhALL2017/COGAALL1631 Prof. LI Chi Kong
李志光
2017.606 A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab versus no Prophylaxis in Hemophilia A Patients Prof. LI Chi Kong
李志光
2017.241 Non-interventional Study on the Safety and Efficacy of Micafungin for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania – ERADICATE Study Prof. LI Chi Kong
李志光
2017.568 An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Prof. LI Chi Kong
李志光教授
2016.247 Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%) Dr. LI Chi Kong
李志光
2017.131 Asparaginase activity and inhibitor in Chinese patients Prof. LI Chi Kong
李志光教授
2015.286 A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A Dr. LI Chi Kong
李志光
2014.364 A Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pediatric patients with severe hemophilia A Dr. LI Chi Kong
2017.440 The prevalence and clinical outcome of Ph-like Acute Lymphoblastic Leukaemia in a retrospective cohort Prof. LI Chi Kong
李志光
2014.462 Phase II Trial of the Addition of Gemcitabine to 131I-MIBG Therapy in Paediatric Patients with Relapsed or Progressive Neuroblastoma Dr. LI Chi Kong
2015.631 Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A Dr. LI Chi Kong
李志光醫生
2019.107 Prevalence of Iron deficiency and its impact on neurocognitive function in Hong Kong adolescent Prof. LI Chi Kong
李志光
2019.519 A single arm, open-labelled Phase II clinical trial of anti-CD19 chimeric antigen receptor modified T-cell (CAR-T) for treatment of B-cell haematological malignancies Prof. LI Chi Kong
李志光教授
2018.099 Lifestyle modification program for treatment of nonalcoholic fatty liver disease in childhood cancer survivors Prof. LI Chi Kong
李志光
2019.173 Life Functioning and Quality of Life in Adult Survivors of Childhood Cancer Prof. LI Chi Kong
李志光
2019.091 A retrospective study on compassionate use of Inotuzumab Ozogamicin in infants and younger children with relapsed or refractory acute lymphoblastic leukemia (ALL) Prof. LI Chi Kong
李志光
2020.445 A Phase II CCCG-ALL Multi-center Trial of Dasatinib in Combination with Intensive Induction Therapy for Children with First Relapsed T-cell Acute Lymphoblastic Leukemia Prof. LI Chi Kong
李志光
2020.035 Evaluation of health-related quality of life and social support among caregivers of paediatric palliative care: A longitudinal prospective study Prof. LI Chi Kong
李志光
2018.303 Registration in Center for International Blood and Marrow Transplant Research Prof. LI Chi Kong
李志光
2020.540 Chinese Children’s Cancer Group Acute Lymphoblastic Leukemia-2020 Project (CCCG-ALL-2020) Prof. LI Chi Kong
李志光
2020.404 Driving Therapeutic Progress of Childhood Leukemia through Advanced Translational Research with Immediate and Long-term Impact Prof. LI Chi Kong
李志光教授
2019.023 Neuroimaging, Cognitive and Life Functioning Outcomes in Patients with Hemophilia Prof. LI Chi Kong
李志光
2019.704 An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis Prof. LI Chi Kong
李志光教授
2019.297 Retrospective review of bone health in transfusion dependent thalassemia patients in Hong Kong Prof. LI Chi Kong
李志光教授
2019.712 The Prognostic factors of paediatric osteosarcoma in Hong Kong Prof. LI Chi Kong
李志光
2021.110 Effect of cancer treatment on testicular function and semen quality in male childhood and adolescent cancer survivors Prof LI Chi Kong
李志光
2021.280 Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia Prof. LI Chi Kong
李志光
2021.314 Effect of cancer treatment in adolescents and early adults on uterus and endometrial function Prof Li Chi Kong
李志光
2013.394 Development and Testing of a Self-management Model for Patients with Chronic Obstructive Pulmonary Disease Miss LI CHING CHING
2022.441 Impact of pre-operative penicillin allergy evaluation on surgical prophylaxis: a randomized controlled trial Dr. LI Chun Man
2022.680 A retrospective study on clinical characteristics and treatment outcomes in patients with acquired haemophilia A (AHA) in Hong Kong Dr. LI Chung Hin
2021.325 Repetitive Negative Thinking of Patients with Common Mental Disorders: The Role of Goal Discrepancy, Rationality, and Psychological Flexibility Ms. LI Connie Suk Man
李淑雯
2011.509 In vivo assessment of periaricular and generalized bone loss in patients with rheumatoid arthritis by high resolution peripheral quantitative computed tomography Prof. LI Edmund
2011.228 Effects of inflammation on bone loss in rheumatoid arthritis: Does inflammation affect joints and bone equally? Professor LI Edmund K
2010.455 A prospective case-control cost of illness studies in systemic lupus erythematosus Prof. LI Edmund K
2011.570 Bone quality in men with rheumatoid arthritis: A case-control study using the high-resolution peripheral quantitative computed tomography Prof. Li Edmund K
2007.083 Genetic Studies of Autoimmune Disease in Chinese Prof. LI Edmund Kwok Ming
2010.298 A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis Professor Li Edmund Kwok Ming
2010.463 In vivo assessment of bone microarchitecture and bone perfusion in osteoporotic patients with systemic lupus erythematosus Prof. Li Edmund Kwok-ming

Page 145 of 254.